Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 101–200 of 860
Talos, D. M., Sun, H., Zhou, X., Fitzgerald, E. C., Jackson, M. C., Klein, P. M., Lan, V. J., Joseph, A., & Jensen, F. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035885 · Cited by 180
“in the mouse are associated with seizures, cognitive disorders and autistic-like behavior”
BackgroundBehavioral phenotypes of genetic mouse models of autism
Kazdoba, T. M., Leach, P. T., & Crawley, J. N. (2016) · Genes, Brain and Behavior · doi:10.1111/gbb.12256 · Cited by 178
“However, Tsc2 mutations did produce learning and memory deficits in Morris water maze hidden platform performance and contextual fear conditioning (Ehninger et al. 2008).”
BackgroundDendritic spine dysgenesis in autism related disorders
Phillips, M., & Pozzo-Miller, L. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.01.011 · Cited by 176
Caccamo, A., Maldonado, M. A., Majumder, S., Medina, D. X., Holbein, W., Magrí, A., & Oddo, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180638 · Cited by 173
Autism and epilepsy: Historical perspective
Tuchman, R., Cuccaro, M., & Alessandri, M. (2010) · Brain and Development · doi:10.1016/j.braindev.2010.04.008 · Cited by 172
“[128] Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski”
BackgroundFeliciano, D. M., Su, T., Lopez, J., Platel, J.-C., & Bordey, A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44909 · Cited by 173
5‐HT 6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia
Meffre, J., Chaumont‐Dubel, S., Mannoury la Cour, C., Loiseau, F., Watson, D. J. G., Dekeyne, A., Séveno, M., Rivet, J., Gaven, F., Déléris, P., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201410 · Cited by 172
“Indeed, our findings encourage an extension of clinical trials of mTOR inhibitors from patients presenting genetic forms of autism-related disorder, like tuberous sclerosis (Auerbach et al, 2011; Ehninger et al, 2008; Ehninger & Silva, 2011), to more numerous populations of schizophrenic patients.”
Epilepsy as a Neurodevelopmental Disorder
Bozzi, Y., Casarosa, S., & Caleo, M. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00019 · Cited by 171
“In contrast with the main feature of the human disease, Tsc1+/− or Tsc2+/− mice do not develop tubers (Kobayashi et al., 2001; Uhlmann et al., 2002; Goorden et al., 2007; Ehninger et al., 2008; Bonnet et al., 2009).”
BackgroundResultInfluentialTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics
Kazdoba, T. M., Leach, P. T., Yang, M., Silverman, J. L., Solomon, M., & Crawley, J. N. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_5003 · Cited by 170
Caccamo, A., Majumder, S., Deng, J. J., Bai, Y., Thornton, F. B., & Oddo, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031278 · Cited by 169
Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
Wong, M. (2013) · Biomedical Journal · doi:10.4103/2319-4170.110365 · Cited by 165
“Although such biomarkers for epilepsy have not been definitely established, future studies might establish specific EEG or brain MRI abnormalities as biomarkers for epilepsy in TSC.”
InfluentialBrooks‐Kayal, A. R., Bath, K. G., Berg, A. T., Galanopoulou, A. S., Holmes, G. L., Jensen, F. E., Kanner, A. M., O'Brien, T. J., Whittemore, V. H., Winawer, M. R., et al. (2013) · Epilepsia · doi:10.1111/epi.12298 · Cited by 167
“Tuberous sclerosis complex is an example in which genetic mutations that cause the disorder affect fundamental neurobiologic phenomena (mammalian target of rapamycin [mTOR] signaling) that can lead to cognitive deficits—independent of seizures (Ehninger et al., 2008; van Eeghen et al., 2012a,b).”
BackgroundDysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism
Huber, K. M., Klann, E., Costa-Mattioli, M., & Zukin, R. S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2656-15.2015 · Cited by 167
“Indeed, the mTORC1 inhibitor rapamycin has shown promising results in PTEN KO mice (Zhou et al., 2009) and TSC2 / mice (Ehninger et al., 2008).”
BackgroundUnifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops
Mullins, C., Fishell, G., & Tsien, R. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.017 · Cited by 167
“In accord with the consensus signaling pathway (Figures 5A1 and 5A2), Ehninger et al. (2008) further demonstrated that abnormalities of LTP and deficiencies in hippocampus-dependent learning tasks in Tsc2+/ animals, in which mTOR signaling is abnormally heightened, can be rescued by the mTOR…”
InfluentialTherapeutic approaches to epileptogenesis—Hope on the horizon
Pitkänen, A. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02602.x · Cited by 167
Borrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 165
The Genetics of Autism: Key Issues, Recent Findings, and Clinical Implications
El-Fishawy, P., & State, M. W. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.002 · Cited by 166
Autism and the synapse: emerging mechanisms and mechanism-based therapies
Ebrahimi-Fakhari, D., & Sahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 167
Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin
Carson, R. P., Van Nielen, D. L., Winzenburger, P. A., & Ess, K. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.024 · Cited by 165
Di Nardo, A., Kramvis, I., Cho, N., Sadowski, A., Meikle, L., Kwiatkowski, D. J., & Sahin, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0778-09.2009 · Cited by 165
“mTOR inhibitors have already been successfully used in several brainspecific TSC mouse models and shown to efficiently improve survival and neurological phenotypes (Ehninger et al., 2008; Meikle et al., 2008; Zeng et al., 2008).”
MethodSelf-citationmTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis
Citraro, R., Leo, A., Constanti, A., Russo, E., & De Sarro, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.039 · Cited by 164
Developmental and epileptic encephalopathies: what we do and do not know
Specchio, N., & Curatolo, P. (2021) · Brain · doi:10.1093/brain/awaa371 · Cited by 164
Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex
Salussolia, C. L., Klonowska, K., Kwiatkowski, D. J., & Sahin, M. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015354 · Cited by 163
Self-citationExercise training improves motor skill learning via selective activation of mTOR
Chen, K., Zheng, Y., Wei, J.-A., Ouyang, H., Huang, X., Zhang, F., Lai, C. S. W., Ren, C., So, K.-F., & Zhang, L. (2019) · Science Advances · doi:10.1126/sciadv.aaw1888 · Cited by 162
The genetics of child psychiatric disorders: focus on autism and Tourette syndrome
State, M. W. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.004 · Cited by 162
“…that targeting of this pathway, as is feasible with rapamycin and other compounds, may provide a novel avenue for treatment (Ehninger et al., 2009; Ehninger et al., 2008), and second, that the data may converge with the biology implicated by fragile X to further refine the understanding of the…”
BackgroundRoles of mTOR Signaling in Brain Development
Lee, D. Y. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.3.177 · Cited by 158
“Moreover, TSC associated intellectual disability is also improved by the treatment of rapamycin in Tsc2+/- mouse models [57].”
BackgroundBehavioral profiles of mouse models for autism spectrum disorders
Ey, E., Leblond, C. S., & Bourgeron, T. (2011) · Autism Research · doi:10.1002/aur.175 · Cited by 161
“The two studies reported respectively reversal of impairments in fear conditioning, spatial learning, locomotion, and brain weight [Ehninger et al., 2008a,b], and reversal of anxiety level, locomotion, social interactions, and seizure duration [Zhou et al., 2009].”
BackgroundDysregulation of the IGF‐I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders
Chen, J., Alberts, I., & Li, X. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.03.006 · Cited by 151
Pagani, M., Barsotti, N., Bertero, A., Trakoshis, S., Ulysse, L., Locarno, A., Misevičiūtė, I., Felice, A. D., Canella, C., Supekar, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26131-z · Cited by 176
Recent advances in neurobiology of Tuberous Sclerosis Complex
Napolioni, V., Moavero, R., & Curatolo, P. (2008) · Brain and Development · doi:10.1016/j.braindev.2008.09.013 · Cited by 152
“[86] recently reported about deficits in learning and memory presented by mice with a heterozygous, inactivating mutation in the TSC2 gene (TSC2 mice), but without any neuropathology or seizures, thus suggesting that other disease mechanisms were involved.”
BackgroundAltered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism
Young, D. M., Schenk, A. K., Yang, S.-B., Jan, Y. N., & Jan, L. Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005620107 · Cited by 143
Andrews, M. G., Subramanian, L., & Kriegstein, A. R. (2020) · eLife · doi:10.7554/elife.58737 · Cited by 154
“Interestingly, the effects of mTOR on learning and memory likely occur via local translational control of protein synthesis in dendrites, which in turn regulate the structural plasticity of synapses (Ehninger et al., 2008; Oddo, 2012; Puighermanal et al., 2009; Tang et al., 2002).”
BackgroundConvulsing toward the pathophysiology of autism
Tuchman, R., Moshé, S. L., & Rapin, I. (2009) · Brain and Development · doi:10.1016/j.braindev.2008.09.009 · Cited by 142
“[128] Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al.”
BackgroundEvolving neurobiology of tuberous sclerosis complex
Crino, P. B. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1085-x · Cited by 144
Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations
Franz, D. N., Bissler, J. J., & McCormack, F. X. (2010) · Neuropediatrics · doi:10.1055/s-0030-1269906 · Cited by 141
Translational Control in the Brain in Health and Disease
Sossin, W. S., & Costa-Mattioli, M. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032912 · Cited by 138
“…activation of mTORC1 by inhibiting upstream suppressors of mTORC1, tuberous sclerosis complex (Tsc) or phosphatase and tensin homolog (Pten), impairs, not enhances, synaptic plasticity and memory formation (von der Brelie et al. 2006; Ehninger et al. 2008; Sperow et al. 2012; Lugo et al. 2013).”
BackgroundA pulse rapamycin therapy for infantile spasms and associated cognitive decline
Raffo, E., Coppola, A., Ono, T., Briggs, S. W., & Galanopoulou, A. S. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.021 · Cited by 139
“Normalization of pathologically dysregulated mTORC1 activity can improve cognition, even in the absence of seizures, because of its central role in cellular physiology, differentiation and communication (Ehninger et al., 2008, 2009).”
mTOR signaling for biological control and cancer
Alayev, A., & Holz, M. K. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24351 · Cited by 157
“Mouse models heterozygous for Tsc2 mutations show memory and learning defects, and some of the behavioral defects are reversed upon treatment with rapamycin (Ehninger et al., 2008).”
BackgroundCusmai, R., Moavero, R., Bombardieri, R., Vigevano, F., & Curatolo, P. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.08.037 · Cited by 137
“Studies in animal models have suggested a biological basis for the cognitive and behavioral deficits associated with TSC, even in the absence of apparent cerebral pathology and spontaneous seizures [34,35].”
BackgroundYang, F., Chu, X., Yin, M., Liu, X., Yuan, H., Niu, Y., & Fu, L. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.02.005 · Cited by 136
Kim, K. C., Lee, D.-K., Go, H. S., Kim, P., Choi, C. S., Kim, J., Jeon, S. J., Song, M., & Shin, C. Y. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8535-2 · Cited by 144
“Extensive investigation is focused on several pharmacological targets such as mGluR5 antagonist MPEP [28–30] and CTEP [74], GABAB agonist arbaclofen [75], ERK inhibitor lovastatin [76], mToR inhibitor rapamycin [77], D2 receptor antagonist risperidone [78], and endocannabinoid receptor antagonists [79] (for a review,…”
BackgroundDwyer, J. M., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.011 · Cited by 151
“Tsc1 heterozygous (+/-) deletion mutant mice exhibit enhanced hippocampal LTP, owing to increased activation of mTOR, and have deficits in spatial and context discrimination learning (most likely as a result of aberrant synaptic activity) that can be reversed by inhibiting mTOR with rapamycin (38).”
Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
Krueger, D. A., Sadhwani, A., Byars, A. W., de Vries, P. J., Franz, D. N., Whittemore, V. H., Filip‐Dhima, R., Murray, D., Kapur, K., & Sahin, M. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.494 · Cited by 133
“For example, just 5 days of sirolimus treatment improved long-term potentiation and hippocampal learning in a TSC2+/ mouse model.(19) A conditional knockout of Tsc1 in cerebellar Purkinje cells alone led to social interaction and reversal learning deficits, which also improved with sirolimus treatment.”
BackgroundTargeting the mTOR Signaling Network for Alzheimer’s Disease Therapy
Wang, C., Yu, J., Miao, D., Wu, Z., Tan, M., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8505-8 · Cited by 142
“Rapamycin treatment application in these mice reduces the hyperactive mTOR signaling and recede these deficits [130, 131].”
BackgroundXie, K., Ryan, D. P., Pearson, B. L., Henzel, K. S., Neff, F., Vidal, R. O., Hennion, M., Lehmann, I., Schleif, M., Schröder, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707337115 · Cited by 134
“To identify possible novel downstream effectors of mTOR, translationally or transcriptionally regulated by mTOR-related cell signaling, we employed the Ribotag technology (SI Appendix, SI Methods) and RNA-seq to define and quantify mRNAs sensitive to modulation of mTOR signaling [using rapamycin to pharmacologically i…”
MethodSelf-citationKas, M. J., Glennon, J. C., Buitelaar, J., Ey, E., Biemans, B., Crawley, J., Ring, R. H., Lajonchere, C., Esclassan, F., Talpos, J., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3268-5 · Cited by 132
Caffeine, Adenosine Receptors, and Synaptic Plasticity
Costenla, A. R., Cunha, R. A., & de Mendonça, A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091384 · Cited by 132
Mechanistic Target of Rapamycin (mTOR) in Tuberous Sclerosis Complex-Associated Epilepsy
Curatolo, P. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.10.028 · Cited by 143
Experimental models of Rett syndrome based on Mecp2 dysfunction
Calfa, G., Percy, A. K., & Pozzo-Miller, L. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010261 · Cited by 132
van Veelen, W., Korsse, S. E., van de Laar, L., & Peppelenbosch, M. P. (2011) · Oncogene · doi:10.1038/onc.2010.630 · Cited by 155
Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets
Vieira, M. N. N., Lima-Filho, R. A. S., & De Felice, F. G. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.014 · Cited by 132
Targeting PI3K-AKT/mTOR signaling in the prevention of autism
Sharma, A., & Mehan, S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105067 · Cited by 129
Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“A comprehensive review of these findings has been published recently (Ehninger et al, 2008b).”
BackgroundMethodInfluentialStamou, M., Streifel, K. M., Goines, P. E., & Lein, P. J. (2013) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2012.12.001 · Cited by 128
“Administration of rapamycin, a specific inhibitor of mTORC1, can reverse aberrant neuronal morphologies and behavioral defects observed in transgenic mice expressing Pten (Zhou et al., 2009) or Tsc1/Tsc2 (Ehninger et al., 2008) mutations and reverse abnormal synaptic functions in adult mouse models of Fragile X (de Vr…”
BackgroundDisruption of mTOR and MAPK pathways correlates with severity in idiopathic autism
Rosina, E., Battan, B., Siracusano, M., Di Criscio, L., Hollis, F., Pacini, L., Curatolo, P., & Bagni, C. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0335-z · Cited by 130
Role of the mTOR signaling pathway in epilepsy
Meng, X., Yu, J., Song, J., Chi, S., & Tan, L. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.05.029 · Cited by 139
“, antiseizure) [74,77] or prevented the development of epilepsy and the underlying molecular and histopathological mechanisms of epileptogenesis (i.”
BackgroundHasskarl, J. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_8 · Cited by 147
A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials
Wong, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.48 · Cited by 119
Lozovaya, N., Gataullina, S., Tsintsadze, T., Tsintsadze, V., Pallesi-Pocachard, E., Minlebaev, M., Goriounova, N. A., Buhler, E., Watrin, F., Shityakov, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms5563 · Cited by 125
A clinical update on tuberous sclerosis complex‐associated neuropsychiatric disorders (TAND)
de Vries, P. J., Wilde, L., de Vries, M. C., Moavero, R., Pearson, D. A., & Curatolo, P. (2018) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31637 · Cited by 121
“Encouraging murine work has supported the possibility that mTOR inhibition may reverse or improve aspects of TAND (Ehninger et al., 2008; Tsai et al., 2012; Waltereit et al., 2011), and have shown that there may be complex combinatorial pathways to TAND (Schneider et al., 2017; Waltereit et al.,…”
BackgroundHow longevity research can lead to therapies for Alzheimer's disease: The rapamycin story
Richardson, A. G., Galván, V., Lin, A., & Oddo, S. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.12.002 · Cited by 126
Targeting the “hallmarks of aging” to slow aging and treat age-related disease: fact or fiction?
Keshavarz, M., Xie, K., Schaaf, K., Bano, D., & Ehninger, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01680-x · Cited by 118
Self-citationYe, X., & Carew, T. J. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.013 · Cited by 121
“Importantly, recent studies suggest that these cognitive impairments can be at least partially reversed by readjusting related neuronal signaling elements (Ehninger et al., 2008; Li et al., 2005).”
BackgroundEhninger, D., De Vries, P. J., & Silva, A. J. (2009) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2009.01208.x · Cited by 120
“2001; Dabora et al. 2002; Kikuchi et al. 2004; Goorden et al. 2007; deVries & Howe 2007; Ehninger et al. 2008a).”
BackgroundMethodSelf-citationEhninger, D., Sano, Y., de Vries, P. J., Dies, K., Franz, D., Geschwind, D. H., Kaur, M., Lee, Y.-S., Li, W., Lowe, J. K., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.115 · Cited by 120
Self-citationA randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex
Overwater, I. E., Rietman, A. B., Mous, S. E., Bindels-de Heus, K., Rizopoulos, D., ten Hoopen, L. W., van der Vaart, T., Jansen, F. E., Elgersma, Y., Moll, H. A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007749 · Cited by 120
Spooren, W., Lindemann, L., Ghosh, A., & Santarelli, L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.004 · Cited by 119
Garelick, M. G., & Kennedy, B. K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.030 · Cited by 128
“In a transgenic mouse model of tuberous sclerosis, rapamycin treatment rescued memory deficits (Ehninger et al., 2008) suggesting that memory impairments are due, at least in part, to abnormal mTOR signaling in adult neurons as opposed to developmental effects of the disease.”
BackgroundTuberous sclerosis complex: tumors and tumorigenesis
Borkowska, J., Schwartz, R. A., Kotulska, K., & Jóźwiak, S. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04727.x · Cited by 119
Gonatopoulos-Pournatzis, T., Niibori, R., Salter, E. W., Weatheritt, R. J., Tsang, B., Farhangmehr, S., Liang, X., Braunschweig, U., Roth, J. F., Zhang, S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.006 · Cited by 127
“…disorder caused by loss-of-function mutations in TSC1 or TSC2 genes, is frequently characterized by autistic-like phenotypes that can be rescued by pharmacomodulation of mTOR signaling, which controls translation initiation (Auerbach et al., 2011; Borrie et al., 2017; Ehninger et al., 2008).”
BackgroundSantini, E., & Klann, E. (2014) · Science Signaling · doi:10.1126/scisignal.2005832 · Cited by 118
“However, it should be noted that specific genetic ablation of Tsc1 in either astrocytes (68) or neurons (66, 69) results in epilepsy and lethality.”
BackgroundPostnatal lesion evidence against a primary role for the corpus callosum in mouse sociability
Yang, M., Clarke, A. M., & Crawley, J. N. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06714.x · Cited by 117
“…& Insel, 2002; Young et al., 2002; Long et al., 2004; Takayanagi et al., 2005; Cheh et al., 2006; Kwon et al., 2006; Mineur et al., 2006; Crawley et al., 2007; Tabuchi et al., 2007; Chadman et al., 2008; Ehninger et al., 2008; Hung et al., 2008; Jamain et al., 2008; Scearce-Levie et al., 2008;).”
Kelleher III, R. J., Geigenmüller, U., Hovhannisyan, H., Trautman, E., Pinard, R., Rathmell, B., Carpenter, R., & Margulies, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035003 · Cited by 116
“Identification of the genes responsible for recognized neurogenetic syndromes with high prevalence of ASD, such as FMR1 and TSC1/2, and localization of causative genes within microdeletions associated with non-syndromic (idiopathic) autism, such as SHANK3, NLGN3, and NLGN4, have highlighted the role of single-gene mut…”
InfluentialMukhtar, I. (2020) · Seizure · doi:10.1016/j.seizure.2020.09.015 · Cited by 130
mTOR Inhibitors in Tuberous Sclerosis Complex
Curatolo, P., & Moavero, R. (2012) · Current Neuropharmacology · doi:10.2174/157015912804143595 · Cited by 112
mTOR, a Potential Target to Treat Autism Spectrum Disorder
Sato, A. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160413120638 · Cited by 113
Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage
Brewster, A. L., Lugo, J. N., Patil, V. V., Lee, W. L., Qian, Y., Vanegas, F., & Anderson, A. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057808 · Cited by 112
STRADα deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice
Orlova, K. A., Parker, W. E., Heuer, G. G., Tsai, V., Yoon, J., Baybis, M., Fenning, R. S., Strauss, K., & Crino, P. B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41592 · Cited by 111
Sun, Y.-X., Ji, X., Mao, X., Xie, L., Jia, J., Galván, V., Greenberg, D. A., & Jin, K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131124 · Cited by 127
“Animal model studies have found hyperactive mTOR signaling in the hippocampus of animals modeling tuberous sclerosis with cognitive impairment [18].”
The role of eEF2 pathway in learning and synaptic plasticity
Taha, E., Gildish, I., Gal-Ben-Ari, S., & Rosenblum, K. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.04.015 · Cited by 111
Autism spectrum disorders: The quest for genetic syndromes
Zafeiriou, D. I., Ververi, A., Dafoulis, V., Kalyva, E., & Vargiami, E. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32152 · Cited by 107
Targeted Treatments for Cognitive and Neurodevelopmental Disorders in Tuberous Sclerosis Complex
de Vries, P. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.001 · Cited by 91
“, water maze and context discrimination), were reversed to be indistinguishable from wild-type mice.(33) The group unfortunately were not able to examine the effect of rapamycin on the radial maze task, which showed interesting similarity to human cognitive profiles.”
BackgroundResultInfluentialDrug discovery for autism spectrum disorder: challenges and opportunities
Ghosh, A., Michalon, A., Lindemann, L., Fontoura, P., & Santarelli, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4102 · Cited by 108
Ruppe, V., Dilsiz, P., Reiss, C. S., Carlson, C., Devinsky, O., Zagzag, D., Weiner, H. L., & Talos, D. M. (2014) · Epilepsia · doi:10.1111/epi.12545 · Cited by 109
“to decreased Tsc1/Tsc2 activity leads to increased neuronal size, altered dendritic arborizations and spine formation,(21,22) enhanced glutamatergic neurotransmission,(21,23) altered axonal pathfinding and growth,(24,25) as well as impaired synaptic plasticity.(26,27) Similarly, dysplastic neurons in human cortical tu…”
BackgroundBuckley, A. W., & Holmes, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022749 · Cited by 106
“Rapamycin, an mTOR inhibitor, not only reverses abnormal synaptic consolidation but also restores learning deficits in Tsc2þ mice (Ehninger et al. 2008).”
InfluentialSocial peers rescue autism‐relevant sociability deficits in adolescent mice
Yang, M., Perry, K., Weber, M. D., Katz, A. M., & Crawley, J. N. (2011) · Autism Research · doi:10.1002/aur.163 · Cited by 106
“Animal models of autism provide preclinical tools to evaluate treatment interventions, including behavioral and pharmacological therapeutics (Blundell et al., 2010; Chadman, Yang, & Crawley, 2009; Dolen et al., 2007; Ehninger et al., 2008; Silverman et al., 2009; Silverman et al., 2010; M. Yang et al., 2010; M. Yang e…”
BackgroundInfluentialTSC1/TSC2 signaling in the CNS
Han, J. M., & Sahin, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.02.001 · Cited by 105
“The first heterozygous mouse models of TSC established that haploinsufficiency of either Tsc1 or Tsc2 causes neurocognitive deficits such as impaired hippocampal-dependent learning, social behavior, synaptic plasticity, learning and memory [84,85].”
BackgroundmTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders
Ryskalin, L., Limanaqi, F., Frati, A., Busceti, C. L., & Fornai, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082226 · Cited by 120
mTOR Inhibitors in Tuberous Sclerosis Complex
Curatolo, P., & Moavero, R. (2012) · Current Neuropharmacology · doi:10.2174/157015912804499537 · Cited by 105
GABAergic Circuit Dysfunctions in Neurodevelopmental Disorders
Chattopadhyaya, B., & Cristo, G. D. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00051 · Cited by 125
“In addition, pharmacological treatments have been shown to improve memory impairments in mouse models of Tuberous Sclerosis (Ehninger et al., 2008; Auerbach et al., 2011) or Fragile X Syndrome (Krueger and Bear, 2011).”
BackgroundSensitive time-windows for susceptibility in neurodevelopmental disorders
Meredith, R. M., Dawitz, J., & Kramvis, I. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.03.005 · Cited by 115
Deregulated mTOR-mediated translation in intellectual disability
Troca-Marín, J. A., Alves-Sampaio, A., & Montesinos, M. L. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.01.005 · Cited by 118
Caccamo, A., Branca, C., Talboom, J. S., Shaw, D. M., Turner, D., Ma, L., Messina, A., Huang, Z., Wu, J., & Oddo, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2781-15.2015 · Cited by 105
Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
Abate, G., Uberti, D. L., & Tambaro, S. (2021) · Biology · doi:10.3390/biology10060542 · Cited by 123
Neuronal Autophagy and Neurodevelopmental Disorders
Lee, K.-M., Hwang, S.-K., & Lee, J.-A. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.3.133 · Cited by 103
“In contrast, brief treatment of rapamycin in TSC2 mice shows reversal of learning deficits along with enhancement of late-phase LTP (long-term potentiation) [52].”
BackgroundCellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids
Puighermanal, E., Busquets-García, A., Maldonado, R. J., & Ozaita, A. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0384 · Cited by 115
Pathogenetic mechanisms of focal cortical dysplasia
Marin‐Valencia, I., Guerrini, R., & Gleeson, J. G. (2014) · Epilepsia · doi:10.1111/epi.12650 · Cited by 100
“In mice with inactivated TSC1, rapamycin prevented epilepsy and premature death when administered at early age, and ameliorated seizure frequency and prolonged survival when given at later stages.72 Moreover, rapamycin recued the synaptic plasticity and behavioral deficits of mice with inactivating mutation of TSC2.”
BackgroundInfluentialZhou, M., Li, W., Huang, S., Song, J., Kim, J. Y., Tian, X., Kang, E., Sano, Y., Liu, C., Balaji, J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.033 · Cited by 100
“Neurodevelopmental disorders have long been thought to be caused by irreversible changes during development (Ehninger et al., 2008b).”
BackgroundInfluentialSelf-citationRapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats
Chauhan, A., Sharma, U., Jagannathan, N. R., Reeta, K. H., & Gupta, Y. K. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.08.035 · Cited by 100
MeCP2 and Rett syndrome: reversibility and potential avenues for therapy
Gadalla, K. K. E., Bailey, M. E. S., & Cobb, S. R. (2011) · Biochemical Journal · doi:10.1042/bj20110648 · Cited by 98
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.